Table 4.
Effect size results for uncontrolled trials (UCT)
| Study | Treatment | Total patients | Number of instillations (12 weeks) | VAS BT | VAS AT | VAS ↓ | RR (%) | VAS effect size | RR effect size | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | d | Min | Max | d | Min | Max | ||||||
| Morales et al. [15] | 0,8 % HMW-HA (Cystistat®) | 25 | 6 | 6.7 | 2.45 | 2.7 | 3.67 | 4.00 | 71.0 | 1.31 | 0.70 | 1.92 | 2.00 | 1.32 | 2.68 |
| Kallestrup et al. [42] | 20 | 6 | 4.7 | 2.3 | 3.3 | 3.0 | 1.40 | 65.0 | 0.53 | −0.10 | 1.16 | 1.88 | 1.13 | 2.62 | |
| Gupta et al.a [43] | 20 | 6 | – | – | – | – | – | 55.6 | – | – | – | 1.68 | 0.96 | 2.40 | |
| Riedl et al. [16] | 121 | 12 | 8.5 | 1.7 | 3.5 | 2.7 | 5.00 | 85.0 | 2.27 | 1.95 | 2.60 | 2.35 | 2.02 | 2.67 | |
| Engelhardt et al. [40] | 48 | 10 | 8.15 | 1.7 | 2.71 | 1.96 | 5.44 | 85.0 | 2.97 | 2.39 | 3.55 | 2.35 | 1.83 | 2.87 | |
| Steinhoffb [44] | 0.2 % CS (Gepan instill®) |
13 | – | – | – | – | – | – | 92.3 | – | – | – | 2.58 | 1.83 | 3.33 |
| Nordling and van Ophoven [45] | 165 | 8 | 5.2 | 2.57 | 3.3 | 2.57 | 1.90 | 76.7 | 0.74 | 0.52 | 0.96 | 2.13 | 1.86 | 2.4 | |
| Nickel et al. [46] | 2 % CS (Uracyst®/Uropol S®) |
53 | 10 | 6.9 | 1.8 | 4.3 | 2.3 | 2.60 | 60.0 | 1.27 | 0.85 | 1.69 | 1.77 | 1.32 | 2.22 |
| Porru et al. [24] | 1,6 % HA+ 2 % CS (Ialuril®) | 23 | 12 | 5.4 | 2.8 | 3.6 | 2.5 | 1.80 | 46.0 | 0.68 | 0.08 | 1.27 | 1.49 | 0.84 | 2.14 |
| Porru et al. [47] | 20 | 10 | 5.6 | 2.3 | 3.2 | 3.1 | 2.40 | 53.48 | 0.89 | 0.24 | 1.54 | 1.64 | 0.92 | 2.36 | |
| Bade et al. [48] | i-PPS 300 mg | 6 | 24 | 7.5 | 1.38 | 4.17 | 2.3 | 3.33 | 66.7 | 1.81 | 0.47 | 3.15 | 1.91 | 0.55 | 3.28 |
| Daha et al. [17] | 25 | 22 | – | – | – | – | – | 16.0 | – | – | – | 0.82 | 0.25 | 1.4 | |
VAS visual analogue pain score, BT before treatment, AT after treatment, RR response rate, d = Cohen’s d, i-PPS intravesical instillation with 300 mg (three capsules) of Elmiron® + mixed with 50 ml of 0.9 % sodium chloride
a6 weeks
b24 weeks